Sunshine Biopharma (SBFM) EBITDA (2010 - 2026)
Sunshine Biopharma (SBFM) EBITDA from Mar 31, 2010 to Mar 31, 2026. The TTM Sunshine Biopharma (SBFM) EBITDA is -$5.98M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Sunshine Biopharma (SBFM) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +71.35% |
| 3 Years TTM | -39.89% |
| 5 Years TTM | +32.58% |
| 10 Years TTM | +23.93% |
Annual EBITDA change of Sunshine Biopharma (SBFM)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$1.32M | -77.59% |
| 2025 | -$5.89M | +5.37% |
| 2024 | -$5.59M | +20.47% |
| 2023 | -$4.64M | -82.80% |
| 2022 | -$27M | +1010.29% |
| 2021 | -$2.43M | +333.93% |
| 2020 | -$560K | -11.11% |
| 2019 | -$630K | -43.24% |
| 2018 | -$1.11M | +30.59% |
| 2017 | -$850K | -8.60% |
| 2016 | -$930K | +19.23% |
| 2015 | -$780K | -55.68% |
| 2014 | -$1.76M | -29.32% |
| 2013 | -$2.49M | +250.70% |
| 2012 | -$710K | +26.79% |
| 2011 | -$560K | +3.70% |
| 2010 | -$540K | -1.82% |
| 2009 | -$550K | N/A |
Comparison Sunshine Biopharma (SBFM) five years EBITDA CAGR with competitors
Sunshine Biopharma (SBFM) five years EBITDA CAGR is 70.04%.